Researchers have identified a vitamin B12-based compound capable of crossing the blood-brain barrier in experimental models, offering a potential delivery vehicle for neurological drugs traditionally blocked from reaching central nervous system targets effectively.
The compound exploits transcobalamin transport pathways that naturally shuttle B12 into brain tissue, attaching therapeutic payloads without losing penetration capability during circulation. Tests in rodents demonstrated measurable central accumulation of linked molecules absent in controls receiving untagged drugs.
Neurological conditions including glioblastoma, Alzheimer’s disease and rare enzyme deficiencies suffer from poor drug bioavailability across the barrier composed of tightly joined endothelial cells. Decades of nanotechnology attempts yielded limited clinical successes due to manufacturing complexity.
Teams caution that rodent barrier physiology differs from humans and scaling synthesis under good manufacturing practice standards remains unfinished. Regulatory pathways for hybrid vitamin-drug conjugates may require novel classification discussions with FDA reviewers.
SciTechDaily reported the discovery among biotechnology highlights on May 25, 2026. Venture investors specializing in neurotherapeutics scheduled diligence meetings with the university technology transfer office following embargo lift.
Independent chemists praised modular conjugation chemistry enabling substitution of alternate payloads for different indications.
Neurology drug developers said B12 conjugation platforms could eventually deliver chemotherapy or enzyme replacement therapies that currently cannot penetrate the blood-brain barrier efficiently.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://scitechdaily.com/